Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer.
In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.
We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.
Prostate cancer and prostatic diseases. 2024 Oct 01 [Epub ahead of print]
Andrew J Armstrong, Amy Taylor, Michael C Haffner, Wassim Abida, Alan H Bryce, Lawrence I Karsh, Scott T Tagawa, Przemyslaw Twardowski, Anthony V Serritella, Joshua M Lang
Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University Medical Center, Durham, NC, USA., University of Wisconsin, Madison, WI, USA., Fred Hutchinson Cancer Center, Seattle, WA, USA., Memorial Sloan Kettering Cancer Center, New York, NY, USA., City of Hope, Goodyear, AZ, USA., The Urology Center of Colorado, Denver, CO, USA., Weill Cornell Medicine, New York, NY, USA., Saint John's Cancer Institute, Santa Monica, CA, USA., University of Wisconsin, Madison, WI, USA. .